Orion EBIT per Share
The EBIT per Share of Orion (271560.KS) as of Aug 4, 2026 is 13,751.69 KRW. In the previous year, EBIT per Share was 12,456.52 KRW — a change of 10.40% (higher).
Get this data via API
Financial Data API
EBIT per Share
13,751.69KRW
YoY
10.40%
Last updated:
EBIT per Share of Orion is 2026 13,751.69 KRW. EBIT per Share of Orion was 2025 12,456.52 KRW. It decreases by 10.40% higher compared to the previous year.
Access this data via the Eulerpool API
Orion Stock analysis
What does Orion do? Orion Corp is a Finnish company that operates in the pharmaceutical industry. The company was founded in 1917 and is headquartered in Espoo, Finland. Orion Corp specializes in the development, manufacturing, and marketing of medications, as well as the diagnosis and treatment of diseases.
As one of the leading pharmaceutical companies in Finland, Orion Corp is dedicated to researching and developing medications and medical devices to help doctors and their patients worldwide improve their quality of life.
Orion Corp's business model focuses on selling prescription and over-the-counter medications, as well as manufacturing generic medications. Additionally, the company is involved in the diagnosis and treatment of diseases such as Parkinson's, cancer, and asthma.
The company's main business is centered around three main divisions: pharmaceuticals, diagnostics, and animal health. Within these divisions, Orion Corp has various business areas.
In the pharmaceutical division, the focus is on developing medications to combat Parkinson's, cancer, and asthma. The company has a strong product range of Parkinson's treatments that can alleviate symptoms and slow the progression of the disease. Furthermore, the company is involved in the development of cancer medications that can inhibit the growth of cancer cells.
Orion Corp is also a key player in asthma treatment. The company produces medications that expand the airways and make breathing easier.
In the diagnostics division, Orion Corp's main business is the development and manufacturing of diagnostic devices for diseases such as lung cancer and asthma, as well as products for monitoring blood sugar and cholesterol.
Animal health is another important business area for Orion Corp. The company manufactures medications and accessories for animal health and offers a variety of products to veterinarians and breeders. These include, for example, animal vaccines or hormone preparations to increase fertility in animals.
Orion's production facilities are located in six countries, including Finland, Germany, France, Russia, the USA, and India. Production within the company primarily takes place in Finland.
In addition to manufacturing medications and medical devices, Orion Corp is also a leading producer and developer of raw materials and intermediates for pharmaceutical applications worldwide.
In summary, Orion Corp offers a wide range of products and services in the health and animal health fields using the latest scientific knowledge and technologies. The company remains committed to continuously expanding its product and service portfolio and providing patients worldwide with high-quality and effective medications that positively impact their lives. Orion is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Orion stock
EBIT per Share of Orion is 13,751.69 KRW in 2026.
EBIT per Share of Orion changed from 12,456.52 KRW to 13,751.69 KRW, representing a 10.40% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Orion since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Orion
All Key Metrics — Orion
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth